Clinical Significance of Expression of Periostin in Non-small Cell Lung Cancer.

Abstract

To analyse the expression of serum periostin in patients with non-small cell lung cancer (NSCLC) and its clinical significance. Descriptive study. General Hospital of Ningxia Medical University, Yinchuan, China, from October 2018 to October 2019. Patients with NSCLC, benign lung lesions, and healthy volunteers (controls) were enrolled. Serum periostin level of all the patients with NSCLC was determined by the enzyme-linked immunosorbent assayed upon admission. The receiver operating characteristic (ROC) curve was used to evaluate the value of serum periostin predicting metastasis and recurrence. The serum periostin level in the NSCLC group (n=66) was significantly higher than that of the benign group (n=40), control group (n= 38, p<0.001), and in patients with different T and N stages in the NSCLC group (p<0.001). The serum levels of periostin in patients with metastasis and recurrence within one year were significantly higher than those without that (p<0.001). When the serum periostin level was 54.12 ng/mL, the area under the curve (AUC) predicting postoperative recurrence of NSCLC in patients was 0.739, with 69.23% sensitivity and 75.47% specificity. When the serum periostin level was 42.84 ng/mL, the AUC predicting postoperative metastasis of NSCLC in patients was 0.831, with 80.00% sensitivity and 82.93% specificity. Serum periostin level is possibly related to the progression of NSCLC and exhibited certain predictive values for the prognosis of NSCLC patients. The value of periostin level predicting metastasis was greater than predicting recurrence at the studied levels. Non-small cell lung cancer, Periostin expression, Clinical significance.